Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Reexamination Certificate
2006-09-26
2006-09-26
Wang, Sheng Jun (Department: 1617)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
C424S178100, C424S156100, C424S183100, C424S142100, C424S155100, C424S181100, C530S391700, C530S391900, C530S387100, C530S388150, C530S388220, C530S388800, C530S391300
Reexamination Certificate
active
07112317
ABSTRACT:
The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.
REFERENCES:
patent: 4361544 (1982-11-01), Goldenberg
patent: 4444744 (1984-04-01), Goldenberg
patent: 4456550 (1984-06-01), Dvorak et al.
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4536387 (1985-08-01), Sakamoto et al.
patent: 4867962 (1989-09-01), Abrams
patent: 4925922 (1990-05-01), Byers et al.
patent: 4958009 (1990-09-01), Bjorn et al.
patent: 4980457 (1990-12-01), Jansen et al.
patent: 4981953 (1991-01-01), Barbieri et al.
patent: 5021236 (1991-06-01), Gries et al.
patent: 5024834 (1991-06-01), Houston et al.
patent: 5057313 (1991-10-01), Shih et al.
patent: 5081034 (1992-01-01), Bevilacqua et al.
patent: 5120525 (1992-06-01), Goldenberg
patent: 5191067 (1993-03-01), Lappi et al.
patent: 5308622 (1994-05-01), Casscells et al.
patent: 5342757 (1994-08-01), Garin-Chesa et al.
patent: 5354778 (1994-10-01), Ray et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5403713 (1995-04-01), Bevilacqua et al.
patent: 5504067 (1996-04-01), Morrissey et al.
patent: 5576288 (1996-11-01), Lappi et al.
patent: 5589363 (1996-12-01), Roy et al.
patent: 5632991 (1997-05-01), Gimbrone, Jr.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5659013 (1997-08-01), Senger et al.
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5677181 (1997-10-01), Parish
patent: 5679637 (1997-10-01), Lappi et al.
patent: 5716595 (1998-02-01), Goldenberg
patent: 5719120 (1998-02-01), Letarte et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5830448 (1998-11-01), Vehar
patent: 5830847 (1998-11-01), Letarte et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 5866127 (1999-02-01), Senger et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5874081 (1999-02-01), Parish
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5922688 (1999-07-01), Hung et al.
patent: 5928641 (1999-07-01), Seon
patent: 5942602 (1999-08-01), Wels et al.
patent: 5965132 (1999-10-01), Thorpe et al.
patent: 6004554 (1999-12-01), Thorpe et al.
patent: 6015693 (2000-01-01), Letarte et al.
patent: 6022541 (2000-02-01), Senger et al.
patent: 6037329 (2000-03-01), Baird et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6093399 (2000-07-01), Thorpe et al.
patent: 6107090 (2000-08-01), Bander
patent: 6129915 (2000-10-01), Wels et al.
patent: 6136311 (2000-10-01), Bander
patent: 6150508 (2000-11-01), Murphy et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6190660 (2001-02-01), Seon
patent: 6200566 (2001-03-01), Seon
patent: 6261535 (2001-07-01), Thorpe et al.
patent: 6451312 (2002-09-01), Thorpe
patent: 6582959 (2003-06-01), Kim
patent: 2002/0001566 (2002-01-01), Rajopadhye et al.
patent: 2002/0098187 (2002-07-01), Ferrara et al.
patent: 2003/0086919 (2003-05-01), Rosenblum et al.
patent: 2003/0124147 (2003-07-01), Vallera et al.
patent: 2003/0129223 (2003-07-01), Wartchow et al.
patent: 2003/0133972 (2003-07-01), Danthi et al.
patent: 2003/0180305 (2003-09-01), Rajopadhye et al.
patent: 2003/0190317 (2003-10-01), Baca et al.
patent: 2003/0203409 (2003-10-01), Kim
patent: 2003/0206899 (2003-11-01), Ferrara et al.
patent: 2004/0013640 (2004-01-01), Zardi et al.
patent: 0 255 424 (1988-02-01), None
patent: 0 359 347 (1990-03-01), None
patent: 0 458 878 (1996-09-01), None
patent: 0 484 401 (1996-09-01), None
patent: 0 938 505 (2002-03-01), None
patent: 0 666 868 (2002-04-01), None
patent: 0 669 988 (2003-09-01), None
patent: WO 81/01145 (1981-04-01), None
patent: WO 90/03801 (1990-04-01), None
patent: WO 90/05539 (1990-05-01), None
patent: WO 90/12585 (1990-11-01), None
patent: WO 90/13300 (1990-11-01), None
patent: WO 90/13649 (1990-11-01), None
patent: WO 91/02058 (1991-02-01), None
patent: WO 91/05806 (1991-05-01), None
patent: WO 91/07941 (1991-06-01), None
patent: WO 92/01470 (1992-02-01), None
patent: WO 92/12729 (1992-08-01), None
patent: WO 92/14748 (1992-09-01), None
patent: WO 92/19646 (1992-11-01), None
patent: WO 93/08210 (1993-04-01), None
patent: WO 93/08473 (1993-04-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 94/05328 (1994-03-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/11499 (1994-05-01), None
patent: WO 95/21868 (1995-08-01), None
patent: WO 97/45544 (1997-12-01), None
patent: WO 98/43678 (1998-10-01), None
patent: WO 99/58570 (1999-11-01), None
patent: WO/US00/34337 (2000-06-01), None
patent: WO 01/54723 (2001-08-01), None
patent: WO 03/033514 (2003-04-01), None
patent: WO 03/057831 (2003-07-01), None
Hardman et al. “Goodman & Gilman's The Pharmacological Basis of Therapeutics” (9th ed, 1996) p. 51 and 57-58.
Demur et al., “Effects of an Anti-HLA-DR Immunotoxin on Leukaemia Cells and Hematopoietic Progenitors,”Leukemia Research, 13(12):1047-1054, 1989.
Bregni et al., “Elimination of Clonogenic Tumor Cells from Human Bone Marrow Using a Combination of Monoclonal Antibody:Ricin A Chain Conjugates,”Cancer Research, 46:1208-1213, 1986.
Lowe et al., “Studies on the Reappearance of MHC Class II Antigens on Cells of a Variant Human Lymphoblastoid Line,”Immunology Letters12:263-269, 1986.
Nakahara et al., “The Effectiveness of Anti-Ia-Immunotoxins in the Suppression of MLR,”Transplantation, 42(2):205-211, 1986.
Nakahara et al., “The Effectiveness of Anti-Ia-Immunotoxins in the Suppression of MLR,”Transplantation, 40(1):62-67, 1985.
Thorpe et al., “Modification of the Carbohydrate in Ricin with Metaperiodate Cyanoborohydride Mixtures,”Eur. J. Biochem., 147:197-206, 1985.
European Search Report for European Divisional Application No. 02024529.6, dated May 14, 2003.
Thorpe, “Vascular Targeting Agents as Cancer Therapeutics,”Clin. Can. Res., 10:415-427, 2004.
Fonsatti et al., “Emerging Role of Endoglin (CD105) as a Marker of Angiogenesis with Clinical Potential in Human Malignacies,”Current Cancer Drug Targets, 3:429-434, 2003.
Wang et al., “The Effect of Antibody Against Vascular Endothelial Growth Factor on Tumor Growth and Metastasis,”J. Can. Res. Clin. Oncol., 124(11):615-620, 1998 (Abstract only).
Contag and Bachmann, “The Writing is on the Vessel Wall,”Nature, 429:618-619, 2004.
Oh et al., “Subtractive Proteomic Mapping of the Endothelial Surface in Lung and Solid Tumours for Tissue-Specific Therapy,”Nature, 429:629-635, 2004.
Yokoyama and Ramakrishnan, “Addition of Integrin Binding Sequence to a Mutant Human Endostatin Improves Inhibition of Tumor Growth,”Int. J. Cancer, 111:839-848, 2004.
Storkebaum et al., “VEGF: Once Regarded as a Specific Angiogenic Factor, New Implicated in Neuroprotection,”BioEssays, 26:943-954, 2004.
Stephan et al., “Effect of Rapamycin Alone and in Combination with Antiangiogenesis Therapy in an Orthotopic Model of Human of Human Pancreatic Cancer,”Clin. Can. Res.. 10:6993-7000, 2004.
Osborn et al., “Leukocyte Adhesion to Endothelium in Inflammation,”Cell, 62:3-6, 1990.
June et al., “Role of the CD28 Receptor in T-Cell Activation,”Immunology Today, 11(6):211-216, 1990.
Denekamp, “Vascular Attack as a Therapeutic Strategy for Cancer,”Cancer and Metastasis Reviews, 9:267-282, 1990.
Scott et al., “Anti-CD3 Antibody Induces Rapid Expression of Cytokine GenesIn Vivo,” The Journal of Immunology, 145(7):2183-2188, 1990.
O'Connell & Edidin, “A Mouse Lymphoid Endothelial Cell Line Immortalized by Simian Virus 40 Binds Lymphocytes and Retains Func
Burrows Francis J.
Thorpe Philip E.
Board of Regents , The University of Texas System
Chong Yong S.
Fussey Shelley P. M.
Wang Sheng Jun
LandOfFree
Combined methods and compositions for tumor vasculature... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined methods and compositions for tumor vasculature..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined methods and compositions for tumor vasculature... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3561055